Show simple item record

dc.contributor.authorMashingia, Jane
dc.contributor.authorNgum, Nancy
dc.contributor.authorNdomondo-Sigonda, Margareth
dc.contributor.authorKermad, Adem
dc.contributor.authorBujar, Magda
dc.contributor.authorSalek, Sam
dc.contributor.authorWalker, Stuart
dc.date.accessioned2023-03-22T11:45:01Z
dc.date.available2023-03-22T11:45:01Z
dc.date.issued2023-05-31
dc.identifier.citationMashingia , J , Ngum , N , Ndomondo-Sigonda , M , Kermad , A , Bujar , M , Salek , S & Walker , S 2023 , ' Regulatory performance of the East African Community joint assessment procedure: The way forward for regulatory systems strengthening ' , Regulatory Toxicology and Pharmacology , vol. 140 , 105383 , pp. 1-8 . https://doi.org/10.1016/j.yrtph.2023.105383
dc.identifier.issn0273-2300
dc.identifier.otherJisc: 966760
dc.identifier.otherJisc: 977411
dc.identifier.urihttp://hdl.handle.net/2299/26136
dc.description© 2023 Published by Elsevier Inc. This is an open access article distributed under the Creative Commons Attribution License, to view a copy of the license, see: https://creativecommons.org/licenses/by/4.0/
dc.description.abstractBackground: Seven national medicines regulatory authorities in the East African Community (EAC) have embraced regulatory reliance, harmonization and work sharing through the EAC Medicines Regulatory Harmonization programme. Measuring the performance of regulatory systems provides key baseline information to build on regulatory system-strengthening strategies. Therefore, the aim of the study was to evaluate the regulatory performance of the EAC joint scientific assessment of applications approved between 2018 and 2021. Methods: Utilising a data metrics tool, information was collected reflecting timelines for various milestones including submission to screening, scientific assessment and communication of regional recommendations for biologicals and pharmaceuticals that received a positive regional recommendation for product registration from 2018 to 2021. Results: Several challenges as well as possible solutions were identified, including median overall approval times exceeding the EAC 465-day target and median times to issue marketing authorisation following EAC joint assessment recommendation that far exceeded the 116-day target. Recommendations included establishment of an integrated information management system and automation of the capture of regulatory timelines through the EAC metric tool. Conclusions: Despite initiative progress, work is required to improve the EAC joint regulatory procedure to achieve regulatory systems-strengthening and ensure patients’ timely access to safe, efficacious and quality medicines.en
dc.format.extent8
dc.format.extent3046312
dc.language.isoeng
dc.relation.ispartofRegulatory Toxicology and Pharmacology
dc.subjectAfrican medicines Agency
dc.subjectEAC Medicines regulatory harmonization (MRH)
dc.subjectEast African community (EAC)
dc.subjectJoint scientific assessment
dc.subjectNational medicines regulatory authorities (NMRA)
dc.subjectRegulatory assessment
dc.subjectToxicology
dc.titleRegulatory performance of the East African Community joint assessment procedure: The way forward for regulatory systems strengtheningen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85152009226&partnerID=8YFLogxK
rioxxterms.versionofrecord10.1016/j.yrtph.2023.105383
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record